MKI67 and neoplasm: Accompanying mechanistic studies to our trial revealed an increase in intratumoral CD3+ T-cells and a decrease in tumor Ki-67 expression in the patients who experienced prolonged stable disease/response, evidence that this treatment regimen may produce immunostimulatory antitumor responses.